Sofosbuvir for treatment of chronic hepatitis C

Hepatology International
Sarah KattakuzhyShyam Kottilil

Abstract

Chronic hepatitis C is a leading cause of liver-related morbidity and mortality worldwide. If untreated, chronic hepatitis C can progress to advanced liver fibrosis, cirrhosis, liver failure, hepatocellular carcinoma and death. Until recently, treatment of hepatitis C predominantly constituted an immunomodulatory agent, peg-interferon-alfa and ribavirin. In 2011, the first class of directly acting antiviral agents, HCV NS3/4A serine protease inhibitors, was added to peg-interferon-alfa and ribavirin with increased efficacy. In the past year, an NS5B inhibitor, sofosbuvir, has emerged as a potent agent with pangenotypic efficacy, resulting in the first interferon-free regimen for the treatment of hepatitis C. This review summarizes the data that resulted in regulatory approval of sofosbuvir and highlights the future of hepatitis C therapy with sofosbuvir as the backbone of a highly effective antiviral regimen.

References

Aug 31, 2010·The Journal of Biological Chemistry·Eisuke MurakamiPhillip A Furman
Sep 21, 2011·Annals of Internal Medicine·Vincent Lo ReRobert Gross
Mar 21, 2012·Antimicrobial Agents and Chemotherapy·Angela M LamPhillip A Furman
Jan 4, 2013·The New England Journal of Medicine·Edward J GaneM Michelle Berrey
Mar 9, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Stefan Zeuzem, Federico J Mensa
Apr 24, 2013·The New England Journal of Medicine·Ira M JacobsonUNKNOWN FUSION Study
Apr 24, 2013·The New England Journal of Medicine·Eric LawitzEdward J Gane
Aug 29, 2013·JAMA : the Journal of the American Medical Association·Anuoluwapo OsinusiShyamasundaran Kottilil
Jan 17, 2014·The New England Journal of Medicine·Mark S SulkowskiUNKNOWN AI444040 Study Group
Apr 12, 2014·The New England Journal of Medicine·Kris V KowdleyUNKNOWN ION-3 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-2 Investigators
Apr 15, 2014·The New England Journal of Medicine·Nezam AfdhalUNKNOWN ION-1 Investigators
May 6, 2014·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN VALENCE Investigators
Jun 12, 2014·Expert Review of Clinical Pharmacology·Brian LamZobair Younossi
Jul 20, 2014·JAMA : the Journal of the American Medical Association·Mark S SulkowskiUNKNOWN PHOTON-1 Investigators

❮ Previous
Next ❯

Citations

Nov 13, 2015·Expert Review of Gastroenterology & Hepatology·L TangS Kottilil
Feb 24, 2016·Expert Opinion on Pharmacotherapy·Elana S RosenthalMichael A Polis
Sep 15, 2016·Hepatology International·Chandana PapudesuShashwatee Bagchi
Oct 21, 2017·Expert Opinion on Investigational Drugs·Ameer Abutaleb, Shyamasundaran Kottilil
Nov 12, 2015·World Journal of Gastrointestinal Pharmacology and Therapeutics·Shogo OhkoshiSatoshi Yamagiwa
Dec 9, 2016·Hepatology International·Rebecca LeeEleanor Wilson
Jan 29, 2016·World Journal of Gastroenterology : WJG·Sadhna DhingraSwan N Thung
Jul 27, 2021·Virusdisease·Chayan BhattacharjeeAparna Mukhopadhyay
Aug 10, 2017·Journal of Medicinal Chemistry·Youcef MehellouJan Balzarini

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Related Papers

The Cochrane Database of Systematic Reviews
Kristiana NikolovaJanus C Jakobsen
BMJ : British Medical Journal
Eoin R Feeney, Raymond T Chung
© 2021 Meta ULC. All rights reserved